PMA device
EMBLEM S-ICD Electrode (Lead) Model 3501
Boston Scientific Corporation · Implantable Cardioverter Defibrillator (Non-Crt) (LWS, Class III) · First FDA decision Apr 19, 2018, newest Jul 7, 2026Ventricular arrhythmia and sudden cardiac arrest
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
2
Naming "EMBLEM S-ICD"
MAUDE reports
18,152
Brand "EMBLEM S-ICD", since 2015
PubMed studies
11
Mentioning "EMBLEM S-ICD"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EMBLEM S-ICD Electrode (Lead) Model 3501
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- EMBLEM S-ICD Electrode (Lead) Model 3501PMA supplement
P110042-S210 · Decided Jul 7, 2026 · 113 days after receipt · Normal 180 Day Track No User Fee
Device type: Implantable cardioverter defibrillator (non-CRT) (LWS) · Cardiology
4 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Cardioverter DefibrillatorsNational analysisReview closedCAG-00157R4Updated Nov 19, 2026
- Implantable Cardioverter Defibrillators (ICDs)National determinationOn the books20.4Updated Sep 28, 2026
- Implantable Cardioverter Defibrillators (ICDs)National analysisReview closedCAG-00157NUpdated Sep 15, 2026
- Surveillance of Implantable or Wearable Cardioverter Defibrillators (ICDs): Office, Hospital, Web, or Non-Web BasedLocal determinationIn effectL34087CGS Administrators, LLCUpdated Aug 28, 2026
- Implantable DefibrillatorsNational analysisReview closedCAG-00157R3Updated Nov 20, 2026
- Implantable DefibrillatorsNational analysisReview closedCAG-00157R2Updated Nov 19, 2026
- Implantable Defibrillators - Clinical TrialsNational analysisReview closedCAG-00157RUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "EMBLEM S-ICD", any status and sponsor, newest update first.
- Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia PacingActive, not recruiting
Boston Scientific CorporationPublic (BSX)
NCT04798768 · 297 participants · Start Jul 20, 2021 · Primary completion May 6, 2024
Device: mCRM Therapy System · For: Tachycardia, Ventricular; Arrhythmia, Ventricular
Sites: Phoenix, Arizona; Scottsdale, Arizona; Jonesboro, Arkansas · 38 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EMBLEM S-ICD", and for the whole product code for context.
This brand
18,152 reports: 4,411 malfunction, 13,712 injury, 29 death
Whole product code LWS
240,687 reports: 89,252 malfunction, 148,026 injury, 3,316 death
Newest reports for this brand
- EMBLEM? S-ICDMalfunction
2124215-2026-57737 · Received Oct 30, 2026 · Event dated Oct 20, 2026
Device type: Implantable Cardioverter Defibrillator (Non-Crt) (LWS)
Device problem as coded: Signal Artifact/Noise; Over-Sensing; Inappropriate/Inadequate Shock/Stimulation
Patient problem as coded: Shock from Patient Lead(s)
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- EMBLEM S-ICD Pulse Generator Model A209; Subcutaneous Implantable Cardioverter DefibrillatorOpen, Classified
Z-2441-2023 · Started Jul 11, 2023 · Posted by FDA Aug 22, 2023
Reason given: There is a potential for a rare interaction between the EMBLEM S-ICD and LATITUDE communicator, which may cause S-ICD sensing disablement for a 24-hour interval.
Cause as FDA categorized it: Software design · Device type: Implantable Cardioverter Defibrillator (Non-Crt) (LWS)
10 more recall records with a free account
Published research
The most relevant PubMed records for "EMBLEM S-ICD"[tiab]. The summary above synthesizes these.
- Proper QRS for EMBLEM S-ICD Across Micra Recipients-Pilot Study.
Hrymniak B, Skoczyski P, Skonieczny B, et al. · J Clin Med · 2025
- Boston Scientific EMBLEM S-ICD (Model 3501) lead advisory: an illustrative patient report.
Remole SC, Kohli U, Hassan S · J Interv Card Electrophysiol · 2021
- Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results.
Boersma LV, El-Chami MF, Bongiorni MG, et al. · Heart Rhythm · 2019Multicenter Study, Research Support, Non-U.S. Gov't
- Brugada syndrome: Eligibility for subcutaneous implantable cardioverter-defibrillator after exercise stress test.
von Hafe P, Faria B, Dias G, et al. · Rev Port Cardiol (Engl Ed) · 2021
- Exploiting SMART pass filter deactivation detection to minimize inappropriate subcutaneous implantable cardioverter defibrillator therapies: a real-world single-centre experience and management guide.
Monkhouse C, Wharmby A, Carter Z, et al. · Europace · 2023
- Stepwise Progression and Successful Extraction of a Completely Transected EMBLEM S-ICD Model 3501 Lead.
Morita J, Kasai Y, Kitai T, et al. · J Arrhythm · 2026
- [Modular heart rhythm management : EMPOWERࡊ leadless pacemaker as an add-on to the EMBLEMࡊ S-ICD].
Rudic B, Dürschmied D, Akin I, et al. · Herzschrittmacherther Elektrophysiol · 2025English Abstract
- Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator.
Lloyd MS, Brisben AJ, Reddy VY, et al. · Heart Rhythm O2 · 2023
- Subcutaneous Implantable Cardioverter Defibrillator Lead Repositioning for Preventing Inappropriate Shocks Due to Myopotential Oversensing in a Post-Fulminant Myocarditis Patient.
Sasaki T, Nakamura K, Naito S · Int Heart J · 2019Case Reports
- Inappropriate shocks from subcutaneous and transvenous implantable cardioverter-defibrillators: Reports from the FDA MAUDE database.
Hauser RG, Desouki M, Stanberry LI, et al. · Heart Rhythm O2 · 2026
- Device updates successfully reduce Tߛwave oversensing and inappropriate shocks in subcutaneous ICD patients.
Larbig R, Motloch LJ, Bettin M, et al. · Neth Heart J · 2018
Other devices of this type
Also filed under product code LWS.
- Evera MRI XT DR SureScan Model DDMB1D4Medtronic Cardiac Rhythm Disease Management · PMA 2022
- CurrentAbbott Medical · PMA 2026
- Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)Boston Scientific Corporation · PMA 2022
- Evera S Dr,s Vr Xt Dr, Xt Ve,icd'sMedtronic Cardiac Rhythm Disease Management · PMA 2016
- Gem III At ICDMedtronic, Inc. · PMA 2016
- Entrust ICDMedtronic Cardiac Rhythm Disease Management · PMA 2014
- ENDOTAK RELIANCE / RELIANCE 4-FRONT pace/sense defibrillation leadsBoston Scientific · PMA 2026
- Sprint Quattro Secure S MRI Surescan Lead Model 6935M,SPRINT Quattro Secure MRI Surescan Lead Model 6947MMedtronic, Inc. · PMA 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.